A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 900-909

  Lesimple, Thierry ^a,b   Edeline, Julien ^a   Carrothers, Timothy J ^c   Cvitkovic, Frédérique ^d   Darpo, Borje ^e   Delord, Jean Pierre ^f   Léna, Hervé ^g   Penel, Nicolas ^h   Edwards, Geoff J ⁱ   Law, Kenneth ⁱ   Wanders, Jantien ⁱ   Kristensen, Allan ^j   Reyderman, Larisa ^j  

^a Eugène Marquis Comprehensive Cancer Center   (France)

^b Biotrial   (France)

^c Pharsight   (United States)

^d INSTITUT CURIE   (France)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f INSTITUT CLAUDIUS REGAUD   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ EISAI CO LTD   (Japan)

^j EISAI INC   (United States)

more..

Author keywords

Advanced solid tumors; Cardiac repolarization; E7389; Eribulin mesylate; QT interval

Indexed keywords

ERIBULIN;

ADULT; ADVANCED CANCER; AGED; ALGORITHM; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART RATE; HEART REPOLARIZATION; HEPATITIS; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; SOLID TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ALGORITHMS; CONFIDENCE INTERVALS; DEMOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FURANS; HEART RATE; HUMANS; KETONES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS;

EID: 84880918779     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9893-8     Document Type: Article

References (28)

1. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086-1095
2. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003-2011
3. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331-1337
4. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto C (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15:4207-4212
5. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28:3922-3928
6. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong NY, Fang F, Ashworth S, Rosen LS (2009) Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 15:4213-4218
7. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954-2961
8. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914-923
9. Murphy CG, Seidman AD (2009) Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes. Clin Breast Cancer 9(Suppl 2):S58-S65
10. Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersboll J, Abadie E, Giuliani R, Pignatti F (2012) The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res 18:4491-4497
11. Eisai Inc (2011) Halaven prescribing information. http://www.halaven.com/ . Accessed 30 March 2011
12. Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362-3371
13. Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609-3615
14. Varterasian M, Meyer M, Fingert H, Radlowski D, Asbury P, Zhou X, Healey D (2003) Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol 21:3378-3379
15. Shah RR (2002) Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 16:147-156
16. Shah RR (2002) Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 16:119-124
17. Tornoe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV (2011) Creation of a knowledge management system for QT analyses. J Clin Pharmacol 51:1035-1042
18. International Conference on Harmonisation (2012) International conference on harmonisation E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.ich.org. Accessed 23 January 2012
19. Jonsson MK, Vos MA, Duker G, Demolombe S, van Veen TA (2010) Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology. Pharmacol Ther 127:9-18
20. Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157:827-836
21. Mukohara T, Nagai S, Mukai H, Namiki M, Minami H (2011) Eribulin mesylate in patients with refractory cancers: a phase I study. Invest New Drugs 30:1926-1933
22. Darpo B (2010) The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 159:49-57
23. Fossa AA, Wisialowski T, Magnano A, Wolfgang E, Winslow R, Gorczyca W, Crimin K, Raunig DL (2005) Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 312:1-11
24. Fossa AA, Wisialowski T, Crimin K (2006) QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization. J Pharmacol Exp Ther 316:498-506
25. Malik M (2001) Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12:411-420
26. Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JH (2012) Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs. doi: 10.1007/s10637-012-9829-3
27. Bagnes C, Panchuk PN, Recondo G (2010) Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf 5:93-96
28. Kitagawa K, Kawada K, Morita S, Inada M, Mitsuma A, Sawaki M, Iino S, Inden Y, Murohara T, Imai T, Ando Y (2012) Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol 23:743-747